Abstract: The subject invention provides materials and methods that effectively support innate immunity and/or disperse pathogenic biofilms using readily available, nontoxic, natural substances, while supporting restoration of normal microbiotic homeostasis. In one embodiment, the subject invention provides anti-biofilm compositions comprising one or more probiotic organisms, anti-microbial honey, and other ingredients such as prebiotic compounds, other hive products, green tea derivatives, other plant derivatives, and vitamin D3.

Abstract: Disclosed are compositions of matter, which are extracts of the microalga Aphanizomenon flos Aquae Aquae Rafts ex Born. Rah. Var. flos aquae (AFA-Klamath), and purified components thereof. These compositions are useful for the treatment of neurological and neurodegenerative diseases, and of mood conditions. These diseases and conditions include conditions and disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, hyperactivity and attention deficit disorders, autism, depression, memory deficit, and mood disturbances.

Abstract: The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The novel bacteriophage of the present invention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.

Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a multispecific binding polypeptide, said multispecific binding polypeptide comprising a first binding domain binding to a surface molecule of an immune cell with antitumor activity, preferably a lymphocyte, more preferably a T cell or a dendritic cell, and a second binding domain binding to a tumor-associated antigen; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.

Abstract: Methods for inhibiting exercise-induced production of cortisol, exercise-induced production of myeloperoxidase, exercise-induced production of creatine kinase, and exercise-induced impairment of isometric force generation by administration of nucleotides is disclosed.

Abstract: A method of isolating at least one sphingolipid portion selected from a sphingoid base portion, a ceramide portion, a glycosphingolipid portion or a phosphosphingolipid portion from Cordyceps, in particular from wild-type Cordyceps, allows for obtaining sphingolipid portions having an increased amount of one of sphingoid bases, ceramides, glycosphingolipids or phosphosphingolipids. The sphingolipid portions isolated contained significant amounts of sphingolipids not reported so far, and possess exceptional immunosuppressive activities. A method of treating a subject suffering from an inflammatory disease like an autoimmune disease or an allergic disease includes administering sphingolipids isolated from Cordyceps, in particular from wild-type Cordyceps. A method of treating a subject suffering from an inflammatory disease includes administering certain sphingolipids to the subject.

Abstract: Nutritional supplement compositions for mood enhancement are disclosed. A nutritional supplement composition can include one or more of plant material from pine bark, plant material from a species of the genus Ephedra, caffeine, green tea, octopamine, quercetin, trimethylglycine, yohimbine, and niacin. Some nutritional supplement compositions may affect heart rate, blood pressure, and/or resting metabolic rate when ingested. Related processes are also disclosed.

Abstract: Provided herein are methods of using therapeutically effective compositions of sandalwood oil to treat, prevent or reduce the recurrence of Clostridium infections.

Abstract: Preparation process for dietary supplements, comprising at least two steps, the first step of which is to obtain a basic composition comprising liquid vegetable extracts (that contain alcohol), essential oils, water and optionally powdered vegetable extracts, mineral elements, vitamins, vegetable oils, marine plasma, organic silica, etc., and the second step of which is used to solidify the mixture by adding a solidifying premix comprising alginates, a vegetable gum and optionally solidification retarders such as dry hydrophilic plants, water chelators or other substances, even chemicals. The advantage of the process is that it enables dietary supplements to be obtained in a dry solid state that can be stored at ambient temperature or in a refrigerator, and is stable over time, without losing the nutritional and therapeutic value of the vegetable or natural substances contained therein.

Abstract: A formulation and method for calming hunted animals, which is delivered to a geographic region that has been selected for hunting. The formulations and methods applied in and to a geographic region serve to render hunted animals easier to capture while hunting by administering a calming effect. The formulation and methods include essential oils and other components, which may be delivered to hunted animals via inhalation, ingestion or topical application and any combination thereof to produce the desired result.

Abstract: The present invention provides personal care compositions comprising a carrier and a mixture of essential oil components having specific levels of eucalyptol, terpene materials and auxiliary fragrance materials. The compositions herein gentle to skin and have a fragrance and activity similar if the composition were made using the pure extracted essential oil.

Abstract: Extract and/or fraction from Cinnamomum burmanii (DLBS2411) related to its extraction method and its biological activities show activities as antiulcer by conferring mucoprotection and down-regulating H+/KT+ ATPase. Treatment with DLBS2411 decreases the H+/K+ ATPase mRNA level in HEK 293 and gastric parietal cells. In addition, DLBS2411 inhibits activity of H+/K+ ATPase gastric enzyme wherein pH influences this inhibition mechanism. DLBS2411 also has characteristic as antioxidant which is shown by the increase of reducing power as the given dosage increases.

Abstract: A pharmaceutical composition, including, parts by weight of: 100-170 of a ginkgo flavone, 40-100 of a jujube extract, 100-200 of an extract of a peel of Trichosanthes kirilowii, 30-60 of a saponin of Codonopsis, 50-100 of a saponin of American ginseng, 40-70 of a saponin of Radix astragalu, 20-50 of hirudin, 3-10 of a coenzyme Q10, 40-100 of a longan extract, 20-50 of a modified starch, 100-150 of a carthamin, 100-150 of an extract of peach kernel, 30-50 of a gastordin, 120-200 of a salvianolic acid, 40-90 of an extract of Ligusticum chuanxiong, 100-150 of a saponin of Panax notoginseng, 0-50 of a black sesamin, and 0-50 of an astaxanthin.

Abstract: A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil; coconut oil; soy oil; emu oil; grapefruit seed extract; glycine soja; simmondsia chinensis (Jojoba); lauric acid; chlorhexidine gluconate; ginger oil; lavender oil; peppermint oil; spearmint oil; aloe oil; and a preservative, such as benzalkonium chloride and vitamin E.

Abstract: The present invention relates to the use of novel JNK inhibitor molecules and their use in a method of treatment of the human or animal body by therapy.

Abstract: The present invention generally relates to inhibitors of DUOX1. In some aspects, an inhibitor may be applied to a subject having or being at risk for asthma or other conditions. The inhibitor may be applied by various techniques, such as pulmonary or topical delivery. In some embodiments, the inhibitor may include a peptide or other moiety having a reactive electrophile. The reactive electrophile can target cysteine or other residues within DUOX1 to inhibit its activity, e.g., by covalently binding to the residue. Other non-limiting examples of suitable inhibitors include hydroxynonenal, curcumin, sulforaphane, cinnamaldehyde, dimethyl fumarate, or phenyl vinyl sulfonate. Other aspects of the invention are generally directed to methods of making or using such inhibitors, kits involving such inhibitors, devices or formulations containing such inhibitors, or the like.

Abstract: This document provides methods and materials involved in identifying mammals having blood cancer (e.g., myelomas or lymphomas, including WM, MCL, and DLBCL) that is resistant to treatment with a proteasome inhibitor such as bortezomib (e.g., VELCADE®) as well as methods and materials involved in treating mammals having a blood cancer resistant to a proteasome inhibitor such as bortezomib (e.g., VELCADE®). For example, methods and materials for using the expression level of PSMB9/?1i nucleic acid to identify a mammal as having a blood cancer (e.g., myeloma or lymphoma, such as WM, MCL, or DLBCL) that is resistant to treatment with a proteasome inhibitor such as bortezomib (e.g., VELCADE®) are provided.

Abstract: Provided herein are methods and compositions for treatment of colorectal cancer by administering a caspase inhibitor in combination with chemotherapeutic agents for colorectal cancer.

Abstract: Provided herein are novel compositions, specifically, caveolin modulators, and methods to treat and/or prevent autoimmune and/or inflammatory diseases/conditions using such compositions.

Abstract: The present disclosure relates generally to pharmaceutical compositions comprising an active ingredient and a stabilizing agent, wherein the active ingredient is desmopressin or a pharmaceutically acceptable salt thereof, and wherein the stabilizing agent is one or more gums. The present disclosure further relates to methods of increasing the stability of a pharmaceutical composition comprising desmopressin or a pharmaceutically acceptable salt thereof as an active ingredient; methods for preparing orally disintegrating films comprising desmopressin or a pharmaceutically acceptable salt thereof and orally disintegrating films prepared thereby; and methods of treating or preventing nocturnal enuresis or nocturnal polyuria by administering stabilized pharmaceutical compositions comprising desmopressin or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: An ophthalmic treatment composition for the treatment of dry eye consists essentially of squalane in an amount by weight of 1% to 100%; and mineral oil in an amount by weight of 0% to 99%. Preferably, the mineral oil is a light mineral oil or mixture of light mineral oils and is present in an amount by weight of 1% to 10%. The composition is effectively devoid of water, preservatives, emulsifiers and dispersing agents. A related ophthalmic treatment composition comprises squalane in an amount by weight of 1% to 99% and mineral oil in an amount by weight of 0% to 99% and at least one hydrophobic or lipophilic pharmaceutical substance in an amount by weight of 0.01% to 5%, effective for treatment of at least one ophthalmic condition.

Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

Abstract: Peptide system including at least one peptide blocking the presynaptic release of glutamate. The peptide has the sequence SEQ ID NO 5: GRKKRRQRRRPPIEQSIEQEEGLNRS and/or sequence SEQ ID NO 8: GRKKRRQRRRPPMSEYNATQSDYRER for use in treating pathologies associated with glutamate excitotoxicity.

Abstract: Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor or healthy phenotype.

Abstract: A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.

Abstract: The present inventor has found that glioblastoma cells respond in unique ways to prolactin (Prl) receptor antagonists. The reaction of glioblastoma cells to treatment with Prl receptor antagonists is based on the presence and function of Prl receptors in glioblastomas and the activity can be used for treatment of glioblastomas and other neoplasms of the CNS.

Abstract: The present invention relates to a modified FXN gene providing for increased expression of the encoded protein frataxin that can be used for treatment of Friedreich ataxia.

Abstract: Disclosed herein is a method of promoting sustained survival, sustained regeneration, in a lesioned mature neuron, sustained compensatory outgrowth in a neuron, or combinations thereof. The method comprises contacting the lesioned mature neuron with an effective amount of an inhibitor of PTEN and an effective amount of an inhibitor of SOCS3 to thereby promote survival and/or regeneration and/or compensatory outgrowth of the neuron. Therapeutic methods of treatment of a subject with a neuronal lesion by administration of a therapeutically effective amount of an inhibitor of PTEN and a therapeutically effective amount of an inhibitor of SOCS3, are also disclosed, as are pharmaceutical compositions and devices for use in the methods.

Abstract: A method of using a transfer factor formulation to improve the success rate of a human COS or COS/IUI procedure. The transfer factor formulation consists of at least transfer factor, and may also include lactic acid generating bacteria, and/or glucans. The transfer factor formulation, administered correctly, improves the probability of achieving conception via COS/IUI. Both men and women can receive transfer factor formulation. Dosage amounts are adjusted for body weight. Consumption frequency may be adjusted in response to hormonal measurements. Typically, consumption of the formulation begins three to 100 days before a planned COS/IUI procedure.

Abstract: The invention relates to methods and compositions for treating a neurodegenerative disease. More particularly, the present invention is directed to methods of treatment of neurodegenerative diseases using progranulin and progranulin polypeptides, and methods of treatment of neurodegenerative diseases using effectors, or combinations of effectors, that modify progranulin expression.

Abstract: The present invention pertains to the use of an Integrative pharmacokinetic/pharmacodynamic (PK/PD) ESA-EpoR mathematical model for calculating the binding behaviour of erythropoiesis stimulating agents (ESA). The invention provides methods for the determining of ESA binding sites in cells or patients suffering from anemia. Knowing the amount of ESA binding sites enables the clinical practitioner to optimize the dosage regimen during a treatment of anemia, in particular in patients suffering from a cancerous disease. Further provided are methods for screening ESAs which have a higher specificity for cells strongly expressing the EPO receptor such as colony forming units-erythroid (CFU-E) cells, and not to cells with a low level of EPO receptor cell surface expression, which is the case in cancer cells. Also provided is a computer implemented method, comprising the use of the mathematical model of the invention.

Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.

Abstract: This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using BMP-5 polypeptides to treat rotator cuff conditions as well as methods and materials for using inhibitors of SIRT6, SIRT7, and/or HDAC10 polypeptide expression or activity to treat rotator cuff conditions are provided.

Abstract: The invention provides a method of promoting the host defense of a patient to a bacterial infection comprising administering to a patient suffering or at risk of a bacterial infection, a pharmaceutical composition comprising an effective amount of the pleiotropic cytokine, thymic stromal lymphopoietin (TSLP) protein or polypeptide in an amount and at a location sufficient to promote the host defense of the patient to the bacterial infection. In a preferred embodiment, the bacterial infection is the infection of the patient with MRSA. The invention also provides a method of treating blood product, which comprises introducing a TSLP protein or polypeptide into such blood product, wherein the blood product is extracorporeal and comprises at least one neutrophil.

Abstract: A pharmaceutical composition in which the active substance includes or is: (i) a protein including the sequence SEQ ID NO: 1, representing the APRIL protein, (ii) any derived protein, which is derived from protein of sequence SEQ ID NO: 1 by substitution, removal or addition of one or more amino-acids, provided it allows the binding of the derived protein to an astrocyte and/or CSPG, (iii) any homologous protein, the sequence of which has a percentage of identity of at least approximately 70%, and in particular 85% with the sequence SEQ ID NO: 1, provided it allows the binding of the homologous protein to an astrocyte and/or CSPG, or (iv) any fragment of the protein of sequence SEQ ID NO: 1, provided it allows the binding of the fragment to an astrocyte and/or CSPG. The active substance is in association with an acceptable pharmaceutical vehicle.

Abstract: The present invention relates to Granulocyte colony-stimulating factor (GCSF) for use in the treatment of neurogenic immune depression syndrome, for use in the prevention of mortality after brain injury and for use in the prevention of brain inflammation after brain injury.

Abstract: Methods for generating an anti-inflammatory compositions. Methods include obtaining a biological material, determining input concentrations of an anti-inflammatory cytokine and of an inflammatory cytokine in the biological material wherein the anti-inflammatory cytokine inhibits the activity of the inflammatory cytokine; processing the biological material, and determining output concentrations of the anti-inflammatory cytokine and the inflammatory cytokine in the anti-inflammatory composition. The input and output concentrations are used to calculate a ratio of anti-inflammatory cytokines to inflammatory cytokines in both the output and the input. A ratio of at least 1 indicates that the anti-inflammatory composition is suitable for treating an inflammatory disorder.

Abstract: The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R?-activating amount of a long acting, IL-2R?-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.

Abstract: An ophthalmic composition for administration to an eye containing 0.001-1000 micrograms per ml by weight of thymosin beta 4 (T?4), or an N-terminal variant, a C-Terminal variant, a conservative variant or an isoform thereof, and one or more of a tonicity agent, a buffering agent, a pH adjusting agent, and a solvent, a method of treating an eye of a human for dry eye syndrome by administering an effective amount of the ophthalmic composition to the eye of the human to treat the dry eye syndrome, and a method of treating a cornea of an eye of a human for corneal epithelial thinning by administering an effective amount of the ophthalmic composition to the cornea to treat corneal epithelial thinning.

Abstract: The present invention relates to a novel exenatide analogue, which is an exenatide analogue in which the first to fifteenth amino acids from the C-terminal of the amino acid sequence of exenatide are deleted and a fatty acid is conjugated. The present invention provides a short length exenatide exhibiting almost the same level of anti-diabetic effects compared with that of conventional exenatide and liraglutide, which is an anti-diabetic drug, and capable of reducing the preparation cost of exenatide.

Abstract: Stabilized glucagon formulations are provided, in the form of a clear solution. The formulations include glucagon in a non-aqueous diluent and an antioxidant The diluent and antioxidant are selected to provide a glucagon formulation with increased stability when compared to glucagon without the anti-oxidant and/or the diluent and which shows a comparable onset of action and duration of glucose response. The compositions can be used to treat subjects with very low blood sugar (severe hypoglycemia) that can happen in subjects who have diabetes and use insulin.

Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for treatment of Anorexia Nervosa, safely and without significantly affecting the blood glucose or blood insulin levels of the patient. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.

Abstract: The embodiments herein are concerned with methods and hCVF compositions, including pharmaceutical formulations, useful in complement depletion, the reduction or prevention of unwanted immunogenicity or other immune-related reactions, especially as a consequence of administering a biologic therapy. Such methods and compositions have been found to be effective in complement depletion during more than one administration in the same subject, thereby being useful for prolonged/repeated use.

Abstract: The present invention relates to a product and method of using albumin nanoparticles for augmenting the function or effectiveness of stem cells or precursor cells in vivo. An albumin nanoparticle suspension containing submicron albumin spheres is prepared, with the albumin spheres being capable of augmenting a function and effectiveness of stem cells or precursor cells in vivo. A predetermined amount of the albumin nanoparticle suspension is administered to a patient before or after an onset of at least one condition. The condition is one that can benefit from a healing effect of the stem cells or precursor cells. A function of the stem cells or precursor cells are augmented or improved by the albumin spheres to repair cellular or tissue damage, resulting in decreasing mortality or morbidity of the patient. The albumin spheres can be bound with fibrinogen molecules in vitro or in vivo.

Abstract: The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrodial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.

Abstract: A composition for removal of biofilm in the ears is useful for the treatment of ear infections such as otitis media, particularly those infections caused by Pseudomonas aeruginosa. In general, the composition comprises: (1) a quantity of at least one enzyme that catalyzes the hydrolysis of a bond that connects two monosaccharides in a polysaccharide or that connects a monosaccharide with a protein molecule in a glycoprotein sufficient to break down biofilm in the ear; and (2) a pharmaceutically acceptable carrier suitable for administration into the ear canal. The composition can further include ingredients such as a steroid, lysozyme, lactoferrin, or a peroxidase; if a peroxidase is included, the composition can further include an oxidase to generate peroxide as well as a substrate for the oxidase. The composition can be used in methods for treatment of an ear infection based on the ability of the composition to dissolve biofilm in the ear.

Abstract: The present invention relates in general to the field of intestinal health. In particular, the present inventors have found that a composition comprising lactoferrin can be used in the prevention, amelioration, or treatment of diarrhea. This finding is in particular important because long lasting diarrhea is seen as a common cause of mortality in infants and children.

Abstract: The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(Lys)m;(His)n;(Om)o;(Xaa)x with the majority of residues being selected from Arg, Lys, His, Om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.

Abstract: The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature.

Abstract: This invention relates to novel uses of recombinant clostridial neurotoxins exhibiting decreased duration of effect, in particular uses for the treatment of patients suffering from a limited range of muscle extension, in particular from flexion contracture, in particular flexion contracture of the knee, and more particularly uses for the treatment of such patients having experienced a total knee arthroplasty.